Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Cetuximab in Recurrent/Metastatic SCCHN
NCT00815295Phase 2Completed
- Sponsor
- Duke University
- Start
- Jan 2008
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Duke University. Started Jan 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00815295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00815295.